Ubs Group Ag I Mab Transaction History
Ubs Group Ag
- $397 Billion
- Q1 2024
A detailed history of Ubs Group Ag transactions in I Mab stock. As of the latest transaction made, Ubs Group Ag holds 1,331 shares of IMAB stock, worth $1,996. This represents 0.0% of its overall portfolio holdings.
Number of Shares
1,331
Previous 15,279
91.29%
Holding current value
$1,996
Previous $29,000
93.1%
% of portfolio
0.0%
Previous 0.0%
Shares
17 transactions
Others Institutions Holding IMAB
# of Institutions
45Shares Held
16MCall Options Held
11.9KPut Options Held
3.5K-
Hhlr Advisors, Ltd. Grand Cayman, E96.91MShares$10.4 Million0.29% of portfolio
-
Decheng Capital Management Iii (Cayman), LLC4.17MShares$6.25 Million3.04% of portfolio
-
David A. Siegel Two Sigma Advisers, LP | New York, Ny617KShares$925,6500.0% of portfolio
-
Two Sigma Investments, LP New York, NY576KShares$863,3700.0% of portfolio
-
Temasek Holdings (Private) LTD Singapore, U0567KShares$849,9750.01% of portfolio
About I-Mab
- Ticker IMAB
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 83,098,800
- Market Cap $125M
- Description
- I-Mab, a clinical stage biopharmaceutical company, discovers, develops, and commercializes biologics to treat cancer and autoimmune disorders. It is developing Felzartamab, a CD38 antibody that is in Phase 1b/2a for patients with membranous nephropathy; Eftansomatropin alfa, a long-acting human growth hormone, which has completed Phase 3 clinica...